JP2002526501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002526501A5 JP2002526501A5 JP2000574113A JP2000574113A JP2002526501A5 JP 2002526501 A5 JP2002526501 A5 JP 2002526501A5 JP 2000574113 A JP2000574113 A JP 2000574113A JP 2000574113 A JP2000574113 A JP 2000574113A JP 2002526501 A5 JP2002526501 A5 JP 2002526501A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- compound
- disease
- ring
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 208000020084 Bone disease Diseases 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 125000004076 pyridyl group Chemical group 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010048843 Cytomegalovirus chorioretinitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010063897 Renal ischaemia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 206010043781 Thyroiditis chronic Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000005000 autoimmune gastritis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000001969 capillary hemangioma Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 208000001763 cytomegalovirus retinitis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- -1 methoxy, cyano, nitro, amino, hydroxy, methyl Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10101398P | 1998-09-18 | 1998-09-18 | |
| US60/101,013 | 1998-09-18 | ||
| PCT/US1999/021567 WO2000017204A1 (en) | 1998-09-18 | 1999-09-16 | INHIBITORS OF p38 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002526501A JP2002526501A (ja) | 2002-08-20 |
| JP2002526501A5 true JP2002526501A5 (OSRAM) | 2006-11-24 |
Family
ID=22282668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000574113A Pending JP2002526501A (ja) | 1998-09-18 | 1999-09-16 | ｐ３８のインヒビター |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6635644B2 (OSRAM) |
| EP (1) | EP1114051B1 (OSRAM) |
| JP (1) | JP2002526501A (OSRAM) |
| AR (1) | AR023659A1 (OSRAM) |
| AT (1) | ATE236167T1 (OSRAM) |
| AU (1) | AU761599B2 (OSRAM) |
| CA (1) | CA2339253C (OSRAM) |
| DE (1) | DE69906554T2 (OSRAM) |
| DK (1) | DK1114051T3 (OSRAM) |
| ES (1) | ES2192864T3 (OSRAM) |
| MY (1) | MY117696A (OSRAM) |
| PT (1) | PT1114051E (OSRAM) |
| WO (1) | WO2000017204A1 (OSRAM) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69917296T2 (de) | 1998-08-20 | 2005-05-25 | Smithkline Beecham Corp. | Neue substituierte triazolverbindungen |
| AU2001283237B2 (en) | 2000-08-11 | 2007-09-20 | Vertex Pharmaceuticals Incorporated | Pyridine derivatives as inhibitors of p38 |
| EP2036891A3 (en) | 2001-06-11 | 2009-03-25 | Vertex Pharmaceuticals Incorporated | Isoquinoline inhibitors of P38 |
| CA2474239A1 (en) * | 2002-01-18 | 2003-07-24 | Pharmacia Corporation | Substituted pyridazinones as inhibitors of p38 |
| JP2005538066A (ja) | 2002-07-09 | 2005-12-15 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 新規な抗コリン作用薬及びｐ３８キナーゼ阻害剤を用いた新規な医薬組成物 |
| US7268139B2 (en) | 2002-08-29 | 2007-09-11 | Scios, Inc. | Methods of promoting osteogenesis |
| EP1585511B1 (en) | 2002-12-20 | 2013-01-23 | Amgen Inc. | Asthma and allergic inflammation modulators |
| ATE534649T1 (de) | 2003-05-15 | 2011-12-15 | Arqule Inc | Imidazothiazole und imidazoxazolderivative als inhibitoren von p38 |
| WO2005007632A1 (en) * | 2003-07-18 | 2005-01-27 | Pharmacia Corporation | Substituted pyridazinones as inhibitors of p38 |
| US7244441B2 (en) | 2003-09-25 | 2007-07-17 | Scios, Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
| JP4608888B2 (ja) * | 2004-01-23 | 2011-01-12 | 宇部興産株式会社 | ２−シアノ−２−（４−テトラヒドロピラニル）酢酸エステルの製法 |
| US7829560B2 (en) | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| EP2258704A1 (en) | 2004-10-19 | 2010-12-08 | ArQule, Inc. | Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| EP1676574A3 (en) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Methods for promoting survival of transplanted tissues and cells |
| US20060178388A1 (en) * | 2005-02-04 | 2006-08-10 | Wrobleski Stephen T | Phenyl-substituted pyrimidine compounds useful as kinase inhibitors |
| US7759337B2 (en) * | 2005-03-03 | 2010-07-20 | Amgen Inc. | Phthalazine compounds and methods of use |
| JP5000649B2 (ja) | 2005-07-21 | 2012-08-15 | エフ．ホフマン−ラ ロシュ アーゲー | 甲状腺ホルモン受容体アゴニストとしてのピリダジノン誘導体 |
| US7482345B2 (en) * | 2005-12-05 | 2009-01-27 | Meng-Hsin Chen | P38 kinase inhibiting agents |
| DK1976828T3 (en) | 2005-12-29 | 2017-03-06 | Celtaxsys Inc | DIAMINE DERIVATIVES AS INhibitors of Leukotriene A4 HYDROLASE |
| CA2649543A1 (en) * | 2006-04-21 | 2007-11-01 | Amgen Inc. | Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use |
| CA2656507C (en) * | 2006-07-17 | 2012-03-20 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| US8101612B2 (en) * | 2006-09-05 | 2012-01-24 | Amgen Inc. | Phthalazine compounds and methods of use |
| US7700593B2 (en) * | 2006-10-11 | 2010-04-20 | Amgen Inc. | Imidazo- and triazolo-pyridine compounds and methods of use thereof |
| EP2131858A4 (en) * | 2007-03-20 | 2011-11-23 | Cadila Pharmaceuticals Ltd | P38 INHIBITORS |
| US8022085B2 (en) * | 2007-05-07 | 2011-09-20 | Amgen Inc. | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof |
| WO2008137176A1 (en) * | 2007-05-07 | 2008-11-13 | Amgen Inc. | Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| US8314131B2 (en) * | 2007-09-21 | 2012-11-20 | Amgen Inc. | Triazole fused heteroaryl compounds and methods of use thereof |
| WO2009078992A1 (en) * | 2007-12-17 | 2009-06-25 | Amgen Inc. | Linear tricyclic compounds as p38 kinase inhibitors |
| EA201001029A1 (ru) | 2007-12-19 | 2011-06-30 | Амген Инк. | Производные фенилуксусной кислоты в качестве модуляторов процесса воспаления |
| US8367671B2 (en) * | 2008-03-21 | 2013-02-05 | Amgen Inc. | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents |
| ES2387474T3 (es) | 2008-08-29 | 2012-09-24 | Amgen, Inc | Compuestos de piridazino-piridinona para el tratamiento de enfermedades mediadas por proteína cinasa |
| EP2334673A1 (en) | 2008-08-29 | 2011-06-22 | Amgen Inc. | PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF |
| WO2010042649A2 (en) | 2008-10-10 | 2010-04-15 | Amgen Inc. | PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF |
| US8772481B2 (en) | 2008-10-10 | 2014-07-08 | Amgen Inc. | Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof |
| WO2010077955A1 (en) | 2008-12-17 | 2010-07-08 | The Scripps Research Institute | Generation and maintenance of stem cells |
| GB0902648D0 (en) * | 2009-02-17 | 2009-04-01 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
| GB0908317D0 (en) * | 2009-05-14 | 2009-06-24 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
| US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| EP2843049B1 (en) | 2012-04-27 | 2018-04-11 | Keio University | Neuronal differentiation promoter |
| JP6527851B2 (ja) | 2013-03-12 | 2019-06-05 | セルタクシス，インコーポレイテッド | ロイコトリエンａ４加水分解酵素を阻害する方法 |
| MX2015011676A (es) | 2013-03-14 | 2016-04-25 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
| EP2970309A4 (en) | 2013-03-14 | 2016-11-09 | Celtaxsys Inc | INHIBITORS OF LEUCOTRIENE A4 HYDROLASE |
| MX2015011677A (es) | 2013-03-14 | 2016-07-08 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
| ES2908041T3 (es) | 2015-10-27 | 2022-04-27 | Childrens Hospital Med Ct | Uso de inhibidores de MAPK para reducir la pérdida de células madre hematopoyéticas durante el cultivo ex vivo y la manipulación genética |
| WO2017151409A1 (en) | 2016-02-29 | 2017-09-08 | University Of Florida Research Foundation, Incorporated | Chemotherapeutic methods |
| US10889548B2 (en) | 2018-03-26 | 2021-01-12 | Clear Creek Bio, Inc. | Compositions and methods for inhibiting dihydroorotate dehydrogenase |
| AU2019278935B2 (en) | 2018-05-31 | 2025-02-13 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
| US20210315880A1 (en) | 2020-03-20 | 2021-10-14 | Clear Creek Bio, Inc. | Methods of treating viral infections using inhibitors of nucleotide synthesis pathways |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| AU2001283237B2 (en) * | 2000-08-11 | 2007-09-20 | Vertex Pharmaceuticals Incorporated | Pyridine derivatives as inhibitors of p38 |
-
1999
- 1999-09-15 AR ARP990104643A patent/AR023659A1/es unknown
- 1999-09-16 AT AT99948314T patent/ATE236167T1/de not_active IP Right Cessation
- 1999-09-16 DE DE69906554T patent/DE69906554T2/de not_active Expired - Lifetime
- 1999-09-16 AU AU61521/99A patent/AU761599B2/en not_active Ceased
- 1999-09-16 CA CA002339253A patent/CA2339253C/en not_active Expired - Fee Related
- 1999-09-16 WO PCT/US1999/021567 patent/WO2000017204A1/en not_active Ceased
- 1999-09-16 EP EP99948314A patent/EP1114051B1/en not_active Expired - Lifetime
- 1999-09-16 ES ES99948314T patent/ES2192864T3/es not_active Expired - Lifetime
- 1999-09-16 PT PT99948314T patent/PT1114051E/pt unknown
- 1999-09-16 DK DK99948314T patent/DK1114051T3/da active
- 1999-09-16 JP JP2000574113A patent/JP2002526501A/ja active Pending
- 1999-09-17 MY MYPI99004032A patent/MY117696A/en unknown
-
2001
- 2001-03-16 US US09/809,921 patent/US6635644B2/en not_active Expired - Fee Related
-
2003
- 2003-09-08 US US10/658,111 patent/US7169779B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002526501A5 (OSRAM) | ||
| JP2002526482A5 (OSRAM) | ||
| JP2002517486A5 (OSRAM) | ||
| JP2002514625A5 (OSRAM) | ||
| JP2009509961A5 (OSRAM) | ||
| HRP20120900T1 (hr) | Inhibitori p38 kinaze bazirani na peteroäślanom heterociklu | |
| CA2331460A1 (en) | Heterocyclic inhibitors of p38 | |
| JP2002543185A5 (OSRAM) | ||
| JP2019517487A5 (OSRAM) | ||
| JP2001525359A5 (OSRAM) | ||
| JP2005507380A5 (OSRAM) | ||
| CA2491895A1 (en) | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases | |
| JP2005534684A5 (OSRAM) | ||
| JP2004535447A5 (OSRAM) | ||
| JP2010506854A5 (OSRAM) | ||
| JP2017501234A5 (OSRAM) | ||
| JPWO2021207172A5 (OSRAM) | ||
| JP2003528084A5 (OSRAM) | ||
| MY146279A (en) | Compounds affecting glucokinase | |
| JP2003531103A5 (OSRAM) | ||
| HRP20130155T1 (hr) | Fuzionirani heterocikliäśki spojevi korisni kao modulatori kinaze | |
| JP2004509120A5 (OSRAM) | ||
| AU7652101A (en) | Cinnoline compounds | |
| JP2006514960A5 (OSRAM) | ||
| JP2020517707A5 (OSRAM) |